Matthew Roden, Aktis Oncology CEO
Lilly makes another radiopharma move in collaboration with Aktis Oncology
Eli Lilly is again dipping into the buzzy area of radiopharmaceuticals by way of private biotech Aktis Oncology.
The pharma giant will dish out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
